Protein / target
Tumor necrosis factor ligand superfamily member 13B
Protein at a glance
Biological role
Tumor necrosis factor receptor binding
Strongest disease association
Lupus Erythematosus, Systemic
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA.
View complete UniProt function annotationHide complete annotation
Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response
Subcellular location
Domains and Gene Ontology detail (16)Hide
Domains & features
Gene Ontology
- Ccytoplasm
- Cextracellular region
- Cextracellular space
- Cmembrane
- Cperinuclear region of cytoplasm
- Cplasma membrane
- Fcytokine activity
- Fsignaling receptor binding
- Ftumor necrosis factor receptor binding
- PB cell differentiation
- Pimmune response
- Plymphocyte homeostasis
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same…
- ·cytokine activity
- ·B cell differentiation
- ·immune response
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Tumor necrosis factor ligand superfamily member 13B inhibitor
Indicated for Lupus Erythematosus, Systemic, Lupus Nephritis
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene TNFSF13B
Gene-level evidence surfaced through the gene TNFSF13B that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
7 compounds recorded · 1 approved · 6 in clinical development
View all recorded compounds (7)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Strong
Other modalities — Strong
View underlying tractability evidence (8)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: BELIMUMAB (BLA125370)
- Label change
Label change: BELIMUMAB (BLA761043)
- Indication expanded
Indication expansion: BELIMUMAB (BLA761043)
- Label change
Label change: BELIMUMAB (BLA125370)
- Indication expanded
Indication expansion: BELIMUMAB (BLA761043)
- Label change
Label change: BELIMUMAB (BLA125370)
- Label change
Label change: BELIMUMAB (BLA125370)
- Label change
Label change: BELIMUMAB (BLA761043)
- Indication expanded
Indication expansion: BELIMUMAB (BLA761043)
- Label change
Label change: BELIMUMAB (BLA125370)
- Indication expanded
Indication expansion: BELIMUMAB (BLA125370)
- Safety communication
Drug Safety Update: Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.